Royal Bank of Canada
VTGN icon

Royal Bank of Canada’s VistaGen Therapeutics VTGN Stock Holding History

Royal Bank of Canada’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Buy
+2,127
New +$1.29K ﹤0.01% 6972
2025
Q3 		– Sell
-3,297
Closed -$7K – 7565
2025
Q2 		$7K Buy
3,297
+2,386
+262% +$5.42K ﹤0.01% 6581
2025
Q1 		$2K Sell
911
-948
-51% -$2.68K ﹤0.01% 6601
2024
Q4 		$5K Sell
1,859
-2,642
-59% -$7.43K ﹤0.01% 6553
2024
Q3 		$14K Buy
4,501
+3,420
+316% +$11.7K ﹤0.01% 6237
2024
Q2 		$4K Buy
+1,081
New +$4.68K ﹤0.01% 6627
2024
Q1 		– Sell
-1,437
Closed -$7K – 7652
2023
Q4 		$7K Sell
1,437
-1,423
-50% -$5.38K ﹤0.01% 6597
2023
Q3 		$15K Buy
2,860
+2,711
+1,819% +$12K ﹤0.01% 6292
2023
Q2 		$0 Sell
149
-237
-61% -$831 ﹤0.01% 7696
2023
Q1 		$1K Sell
386
-566
-59% -$2.97K ﹤0.01% 6942
2022
Q4 		$3K Buy
952
+873
+1,105% +$3.29K ﹤0.01% 6883
2022
Q3 		$0 Buy
79
+9
+13% +$89 ﹤0.01% 7914
2022
Q2 		$2K Sell
70
-327
-82% -$11.5K ﹤0.01% 7006
2022
Q1 		$15K Sell
397
-1,056
-73% -$46K ﹤0.01% 6769
2021
Q4 		$85K Buy
1,453
+791
+119% +$51.5K ﹤0.01% 6052
2021
Q3 		$55K Buy
662
+224
+51% +$19.5K ﹤0.01% 6106
2021
Q2 		$41K Buy
+438
New +$32.5K ﹤0.01% 6174
2020
Q2 		– Sell
-7
Closed – – 6935
2020
Q1 		$0 Hold
7
– – ﹤0.01% 7066
2019
Q4 		$0 Hold
7
– – ﹤0.01% 7149
2019
Q3 		$0 Buy
+7
New +$156 ﹤0.01% 7163

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royal Bank of Canada's VTGN Position: Q1 2026 in Review

Royal Bank of Canada opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 2,127 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #6972 among its holdings. This is a return to the name: Royal Bank of Canada previously reported a position in VTGN as recently as Q2 2025.

Royal Bank of Canada first reported a position in VTGN in Q3 2019 and has held it in 20 quarters since. The position peaked at $85K in Q4 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Royal Bank of Canada held 2,127 shares of VistaGen Therapeutics worth $1K as of Q1 2026.
  • VistaGen Therapeutics was a new Royal Bank of Canada position in Q1 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6972 holding.
  • Royal Bank of Canada first reported a position in VistaGen Therapeutics in Q3 2019 and has held it in 20 quarters since.
  • Royal Bank of Canada's VistaGen Therapeutics position peaked at $85K in Q4 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.